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All known g2-herpesviruses encode a cyclin homolog with significant homology to mammalian D-type cyclins. The murine
gammaherpesvirus 68 (gHV68) viral cyclin (v-cyclin) has been shown to be oncogenic when expression is targeted to thymocytes in
transgenic mice and to be critical for virus reactivation from latency. Here, we investigate the interaction of the gHV68 v-cyclin with cellular
cyclin-dependent kinases (cdks). We show that, in contrast to the Kaposi’s sarcoma-associated herpesvirus (KSHV) v-cyclin, the gHV68
v-cyclin preferentially interacts with cdk2 and cdc2 but does not interact with either cdk4 or cdk6. Mutation of conserved residues, predicted
to be involved in cdk binding based on the gHV68 v-cyclin:cdk2 crystal structure, resulted in the loss of both cdk binding and the ability to
mediate phosphorylation of substrates. Like the KSHV v-cyclin, the gHV68 v-cyclin appears to confer expanded substrate specificity to the
cellular cdk binding partners. As expected, the gHV68 v-cyclin:cdk complexes are able to target phosphorylation of histone H1, the
retinoblastoma protein (pRb), and p27Kip1 as assessed using in vitro kinase assays. Notably, hyperphosphorylation of pRb was observed
during wt gHV68 replication in serum-starved murine fibroblasts, but not in cells that were either mock-infected or infected with a v-cyclin
null gHV68. In addition, infection of serum-starved murine fibroblasts also results in a v-cyclin-dependent increase in cdk2-associated
kinase activity and a concomitant decrease in the levels of p27Kip1. Taken together, the latter studies served to validate the results of the in
vitro kinase assays. Finally, in vitro kinase assays revealed that the gHV68 v-cyclin:cdk complexes can also phosphorylate p21Cip1, Bcl-2,
and p53. The latter suggests that, at least in vitro, the gHV68 v-cyclin exhibits functional characteristics of both cyclin E and cyclin A.
D 2005 Elsevier Inc. All rights reserved.Keywords: Gammaherpesvirus; v-cyclin; cdkIntroduction
The mammalian cell cycle is a series of tightly controlled
and elegantly coordinated events leading to, and including,
the replication of cellular DNA and the segregation of this
material to daughter cells. Sequential activation of cyclin-
dependent kinases (cdks) by their cognate cyclin, during
each phase of the cell cycle, is critical to maintaining an
ordered and controlled cycle (Arellano and Moreno, 1997;
Lees, 1995). D-type cyclins are upregulated early in G1 in0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: sspeck@rmy.emory.edu (S.H. Speck).response to mitogens, bind cdk4 and/or cdk6, and this
complex phosphorylates the retinoblastoma protein (pRb),
thereby mediating G1 progression (Harbour et al., 1999;
Sherr, 1993). E-type cyclins, expressed later in G1, bind
cdk2 and mediate transition through the restriction point
(the point at which mitogenic signals are no longer required
for continued cell cycle progression) and the G1/S
transition. Cyclin E:cdk2 hyperphosphorylates pRb to allow
E2F-driven transcription, which in turn upregulates a
number of cell cycle genes (Harbour and Dean, 2000;
Zhang et al., 2000). Cyclin A:cdk2 complexes form during
S-phase and drive S-phase to G2/M, where cyclinB:cdc2
(cdk1) controls the transition into mitosis. In addition to05) 271 – 283
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modifications and through direct protein–protein interac-
tions with members of the INK4 and Cip1/Kip1 families of
cdk inhibitors (CKIs) (Sherr and Roberts, 1999). These
basic components of the cell cycle machinery interact as part
of a vast signaling pathway to carefully control the rate,
timing, and execution of each replicative cycle, and failure
to do so can result in the unrestrained cell division seen as a
hallmark of cancers and other proliferative diseases.
Perturbation of host cell cycle is a common strategy
employed by DNA viruses to achieve a cellular environment
conducive to viral growth. Adenovirus, polyoma virus,
papilloma virus, and many herpesviruses encode genes that
directly alter the host cell cycle or interact with host gene
products to the same end (Swanton and Jones, 2001). g2-
herpesviruses, such as Kaposi’s sarcoma-associated herpes-
virus (KSHV), herpesvirus saimiri (HVS), and murine
gammaherpesvirus 68 (gHV68), each encode a homologue
of mammalian D-type cyclins (Chang et al., 1996; Jung et
al., 1994; Li et al., 1997; Nicholas et al., 1992; Virgin et al.,
1997). These viral cyclins (v-cyclins) likely represent a
direct mechanism by which these viruses interrupt the
normal host cell cycle in favor of the viral life cycle.
The biochemical properties of the KSHV and HVS
v-cyclins have been extensively characterized (Laman et al.,
2000; Mittnacht and Boshoff, 2000; Verschuren et al.,
2004a, 2004b). The KSHV v-cyclin preferentially binds to
and activates cdk6, although it also binds cdk2 and cdk4
with lower affinity (Godden-Kent et al., 1997; Li et al.,
1997; Mann et al., 1999). In contrast, the HVS v-cyclin
only binds cdk6 (Jung et al., 1994). In addition to the
traditional cdk6 substrate pRb, KSHV v-cyclin confers on
cdk6 a wider substrate repertoire, mediating the phosphor-
ylation of a variety of substrates involved in cell cycle
regulation and survival, including histones, p27Kip1,
cdc25A, cdc6, Orc1, and Bcl2 (Ellis et al., 1999; Godden-
Kent et al., 1997; Laman et al., 2001; Li et al., 1997; Mann
et al., 1999; Ojala et al., 2000; Swanton et al., 1997).
Similarly, the HVS v-cyclin:cdk6 complex has been shown
to also phosphorylate histone H1 and pRb (Jung et al.,
1994). However, unlike cellular D-type cyclins, the KSHV
and HVS v-cyclin:cdk complexes are resistant to inhibition
by cellular cdk inhibitors (CKIs) of the Cip1/Kip1 and INK4
families (Swanton et al., 1997), and the KSHV v-cyclin can
form active complexes without activating phosphorylation
of the cdk by CAK (Child and Mann, 2001; Kaldis et al.,
2001). Potential explanations for many of these unique
features were revealed by the analysis of the crystal
structures of the HVS v-cyclin in complex with cdk6
(Schulze-Gahmen et al., 1999) and the KSHV v-cyclin in
complex with cdk6 and the CKI p18INK4c (Jeffrey et al.,
2000). Recent studies have demonstrated the oncogenic
potential of transgenic KSHV v-cyclin expression in
conjunction with inactivation of the p53 tumor suppressor
(Verschuren et al., 2002, 2004a, 2004b). The individual
effects of these biochemical properties are likely to act in asynergistic manner to force cell cycle progression to a point
conducive to viral replication. However, the role of the
KSHV v-cyclin in the context of viral infection remains
unclear due to the narrow host range of KSHV.
In comparison to the KSHV v-cyclin and HVS v-cyclin,
much less is known about the gHV68 viral cyclin. When
expressed as a transgene in mice, it promotes cell cycle
progression of primary lymphocytes and functions as an
oncogene, causing tumors in more than 60% of transgenic
mice before 1 year of age (van Dyk et al., 1999). In the
context of the viral life cycle, the gHV68 v-cyclin is a
critical regulator of reactivation from latency (Hoge et al.,
2000; van Dyk et al., 2000). The crystal structure of the
gHV68 v-cyclin has been determined in complex with cdk2,
showing that, although it makes several novel interactions
with cdk2 when compared to cyclin A, its mechanism for
activation of cdk2 appears similar (Card et al., 2000). The
structural model also offers insights into sequence and
conformational features of the gHV68 v-cyclin that allow it
to evade inhibition by cellular CKIs. However, the
biochemical properties of the gHV68 v-cyclin remain
poorly understood. While it is known that the gHV68 v-
cyclin binds cdk2, phosphorylates pRb, and evades inhib-
ition by p27Kip1 in vitro, the gHV68 v-cyclin has not been
afforded the attention of the KSHV v-cyclin, despite the
advantage of a tractable animal model in which to extend in
vitro structure/function studies.
As discussed above, we have previously shown that the
gHV68 v-cyclin is both an oncogene and a critical regulator
of gHV68 reactivation (van Dyk et al., 1999, 2000). Here,
we present an initial characterization of gHV68 v-cyclin
interaction with cellular cdks and identify potential target
substrates. These studies provide potential mechanisms by
which the gHV68 v-cyclin mediates both cell cycle
progression and requirements for virus reactivation.Results
cHV68 v-cyclin interacts with cdk2 and cdc2, but not cdk4
or cdk6
To begin the characterization of the gHV68 v-cyclin
functional properties, we focused on interactions of the v-
cyclin with cellular cdks. Following transient transfection of
Cos-1 cells with FLAG-v-cyclin and cdk expression vectors,
cells were harvested, immunoprecipitated, and immunoblot-
ted to determine which cdks were found in the FLAG-v-
cyclin immunocomplex. In agreement with previous studies
(Card et al., 2000), cdk2 was shown to co-immunoprecipi-
tate with gHV68 v-cyclin (Fig. 1A). However, neither cdk4
nor cdk6 efficiently co-immunoprecipitated with the v-
cyclin, despite overexpression of each cdk and comparable
immunoprecipitation of FLAG-v-cyclin (Fig. 1B).
Based on inhibition studies showing that the cdc2/cdk2
inhibitor roscovitine can inhibit v-cyclin function (JU and
Fig. 1. gHV68 v-cyclin binds to cdk2, but not cdk4 or cdk6. (A) Cos-1 cells were transfected with pCMV-TAG2B vector control or FLAG epitope-tagged
cyclins E, D or v-cyclin and pCMV-cdk2 (left panel), pCMV-cdk6 (middle panel), or pCMV-cdk4 (right panel). In the analyses of cyclin association with cdk2
and cdk4, a cyclin D1 expression vector was used, while for the analysis of association with cdk6, a cyclin D3 expression vector was used (see Materials and
methods). (B) Cos-1 cells were transfected with pCMV-TAG2B vector control or FLAG epitope-tagged v-cyclin and pCMV-cdk2 (left panel), pCMV-cdk6
(middle panel), or pCMV-cdk4 (right panel). Cells were harvested 48 h post-transfection, lysates prepared, and immunoprecipitations carried out with agarose-
conjugated anti-FLAG antibodies (Sigma). Immunoprecipitates were subjected to 15% SDS-PAGE, transferred to nitrocellulose membranes, and
immunoblotted with the indicated anti-cdk antibody. Membranes were stripped and reprobed with anti-FLAG antibody to verify FLAG-v-cyclin
immunoprecipitation (panel B only). WCL, whole cell lysates (5% of that used for immunoprecipitation).
Fig. 2. gHV68 v-cyclin binds cdc2 in vitro. Cos-1 cells were transfected
with pCMV-TAG2B vector control (lane 1), FLAG-v-cyclin (lane 2),
FLAG-v-cyclin.K104E (lane 3), or FLAG-v-cyclin.E133V (lane 4) and
pCMV-cdc2. 48 h post-transfection, cells were harvested and immunopre-
cipitated with agarose-conjugated anti-FLAG antibody (Sigma). Immuno-
precipitated complexes were subjected to 15% SDS-PAGE, transferred to
nitrocellulose membranes, and immunoblotted with antibody against cdc2.
Membranes were stripped and reprobed with anti-FLAG antibody. WCL,
whole cell lysates (5% of that used for immunoprecipitation).
J.W. Upton et al. / Virology 341 (2005) 271–283 273SHS, unpublished data; see also Fig. 7), we also assessed
binding of the gHV68 v-cyclin to cdc2. As shown in Fig. 2,
co-immunoprecipitations from transfected Cos-1 cells dem-
onstrated that the gHV68 v-cyclin can indeed interact with
cdc2, although less efficiently than with cdk2 (Fig. 2), and
that mutations introduced into the v-cyclin that eliminate
binding to cdk2 (see Fig. 3 and discussion below) also
disrupt interaction with cdc2. Thus, the gHV68 v-cyclin is
distinct from the KSHV v-cyclin in terms of which cellular
cdks it interacts with.
Mutation of conserved residues within the cyclin box of
cHV68 v-cyclin eliminates binding to cellular cdks
Sequence and structural analysis indicated that gHV68 v-
cyclin possessed a number of features conserved among all
cyclins (Card et al., 2000), suggesting that these common
sequences and structures are important in the engagement
and activation of cdks (Lees and Harlow, 1993). We
generated two independent amino acid substitution muta-
tions at conserved sites within the cyclin box, one which
mutated the lysine at residue 104 to a glutamic acid (K104E)
and the other which mutated a glutamic acid at position 133
Fig. 3. Mutations of conserved residues within the cyclin box inhibit
binding of cdk2 to the gHV68 v-cyclin. Cos-1 cells were transfected with
pCMV-TAG2B vector control (lane 1), FLAG-v-cyclin (lane 2), FLAG-v-
cyclin.K104E (lane 3), or FLAG-v-cyclin.E133V (lane 4) and pCMV-cdk2.
48 h post-transfection, cells were harvested and immunoprecipitated with
agarose-conjugated anti-FLAG antibodies (Sigma). Immunoprecipitates
were subjected to 15% SDS-PAGE, transferred to nitrocellulose mem-
branes, and immunoblotted with antibody against cdk2. Membranes were
stripped and reprobed with anti-FLAG antibody. WCL, whole cell lysates
(5% of that used for immunoprecipitation).
Fig. 4. gHV68 v-cyclin complexes phosphorylate histone H1 and pRb in
vitro. (A) Cos-1 cells were transfected with pCMV-TAG2B vector control
(lanes 1 and 3), FLAG-v-cyclin (lanes 2, 4, and 6), FLAG-v-cyclin.E133V
(lane 5), and pCMV-cdk2 (lanes 2–6). 48 h post-transfection, cells were
harvested and immunoprecipitated with agarose-conjugated anti-FLAG
antibodies (Sigma). Immunoprecipitated complexes were resuspended in
kinase reaction buffer with histone H1 (2 Ag) and 10 ACi gATP, and the
reaction allowed to proceed for 30 min at 37 -C. Reactions were subjected
to 15% SDS-PAGE followed by autoradiography. Gels were dried and
exposed to phosphor-screen for 10 min. (B) Cos-1 cells were transfected
with pCMV-TAG2B vector control (lane 1), FLAG-v-cyclin (lane 2), or
FLAG-v-cyclin.E133V (lane 3) and pCMV-cdk2 (lanes 1–3). 48 h post-
transfection, all samples were harvested and immunoprecipitated with
agarose-conjugated anti-FLAG antibodies (Sigma). Immunoprecipitated
complexes were resuspended in kinase reaction buffer with 2 Ag GST-
Cterm-pRb (top panel) or GST (bottom panel) and 10 ACi gATP. The
reaction was allowed to proceed for 30 min at 37 -C. Reactions were
subjected to 15% SDS-PAGE followed by autoradiography. Gels were dried
and exposed to phosphor-screen for 10 min. (C) Cos-1 cells transfected
FLAG-v-cyclin were harvested 48 h post-transfection. Equivalent lysate
aliquots were depleted of the indicated cdk by 3 rounds of immunopre-
cipitation with agarose-conjugated cdk-specific antibodies. Following the
third IP depletion, lysates were split equally, subjected to overnight
immunoprecipitation with anti-FLAG-agarose beads, and used for in vitro
kinase assays using histone H1 (top panel) or GST-Cterm pRb (lower panel)
as exogenous substrate.
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these residues were shown to form critical interactions with
cdk2 (Card et al., 2000). In Cos-1 cells, these mutations
nearly or completely eliminated binding of cdk2 and cdc2 to
the gHV68 v-cyclin (Figs. 2, 3), indicating that the gHV68
v-cyclin binds and activates cdks, in a manner similar to
cellular cyclins. Importantly, neither mutation appeared to
affect the stability of the v-cyclin since both mutants were
expressed at equivalent levels to the wild type v-cyclin.
cHV68 v-cyclin:cdk2 complexes phosphorylate cyclin
E:cdk2 substrates
Since the gHV68 v-cyclin binds and presumably activates
cdks, we first tested the ability of v-cyclin complexes to
phosphorylate histone H1. When overexpressed in Cos-1
cells, in conjunction with cdk2, the v-cyclin-containing
immune complexes strongly phosphorylate histone H1
(Fig. 4A). This activity was not simply due to autophosphor-
ylation of part of the v-cyclin complex since no signal was
detected without the addition of histone H1 substrate or in the
absence of v-cyclin (Fig. 4A). Additionally, the cdk-binding
mutant E133V was unable to phosphorylate histone H1,
presumably due to the lack of cdk binding. Notably, the
gHV68 v-cyclin immunoprecipitated from Cos-1 cells is
capable of phosphorylating H1 without overexpression of
cdk2, although H1 phosphorylation was enhanced upon
overexpression of cdk2 (Fig. 4A).
It has been previously shown that gHV68 viral
cyclin:cdk2 complex can phosphorylate pRb (Card et al.,
2000). To confirm this, we assessed pRb phosphorylation
(Fig. 4B). Immunoprecipitates from Cos-1 cells containing
FLAG-v-cyclin strongly phosphorylate a pRb-GST fusionprotein, and these complexes do not phosphorylate GST
alone (Fig. 4B). As above, the v-cyclin E133V mutant was
unable to phosphorylate pRb above background levels (Fig.
4B). To further assess which endogenous cdks play a role in
v-cyclin phosphorylation of histone H1 and pRb in the in
Fig. 5. gHV68 v-cyclin complexes phosphorylate pRb during lytic infection. NIH3T12 cells were serum-starved for 48 h then infected with wild type gHV68,
v-cyclin.Stop, or mock-infected in serum-free media for 1 h at 37 -C. Cells were harvested at the indicated times, and lysates separated by 7.5% (top panel) or
15% (bottom panel) SDS-PAGE and Western blotted for pRb (top panel) and gHV68 v-cyclin (bottom panel).
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prior to immunoprecipitation of the v-cyclin. Notably,
depletion of cdk2 resulted in a significant decrease in
phosphorylation of histone H1 and a somewhat more
moderate decrease in the observed phosphorylation of pRb
(Fig. 4C). Depletion of cdk1/cdc2 appeared to have little
impact on histone H1 phosphorylation but did appear to
modestly decrease pRb phosphorylation—suggesting that it
might play a role along with cdk2 in targeting v-cyclin
phosphorylation of pRb (Fig. 4C).
To determine whether the v-cyclin mediates pRb phos-
phorylation in vivo, we assessed pRb phosphorylation duringFig. 6. gHV68 v-cyclin complexes phosphorylate the p27Kip1 CKI and target it fo
control (lanes 2 and 3), FLAG-v-cyclin (lanes 1 and 4), or FLAG-v-cyclin.E133V
harvested and immunoprecipitated with agarose-conjugated anti-FLAG antibody (S
buffer with p27Kip1 (2 Ag) and 10 ACi gATP, and the reaction allowed to proceed fo
autoradiography. Gels were dried and exposed to phosphor-screen for 30 min. (B)
with wild type gHV68, v-cyclin.Stop, or mock-infected in serum-free media. Cell
was separated by 12.5% SDS-PAGE and analyzed by Western blot with the indic
with anti-cdk2–agarose and used for in vitro kinase assays directed against GS
actively dividing NIH3T3 cells.virus infection (Fig. 5). NIH3T12 cells were serum-starved
for 72 h, then infected with wild type gHV68, v-cyclin.Stop
(van Dyk et al., 2000), or mock-infected. Cells were
harvested at the indicated times post-infection and subjected
to Western blotting to determine the extent of pRb phosphor-
ylation, as determined by mobility shift (Fig. 5). Infection
with wild type gHV68 demonstrated by 24 h that the majority
of pRB is found in the slower migrating hyperphosphorylated
form, while in cells infected with v-cyclin.Stop or mock-
infected showed little change in the phosphorylation status of
pRb (Fig. 5, top panel). Importantly, the kinetics of pRb
phosphorylation closely parallel the onset of v-cyclinr degradation. (A) Cos-1 cells were transfected with pCMV-TAG2B vector
(lane 5) and pCMV-cdk2 (lanes 3–5). 48 h post-transfection, cells were
igma). Immunoprecipitated complexes were resuspended in kinase reaction
r 30 min at 37 -C. Reactions were subjected to 15% SDS-PAGE followed by
Contact-inhibited serum-starved NIH3T3 cells were infected at MOI = 10.0
s were harvested at the indicated times, and 100 Ag total protein per sample
ated antibody or 300 Ag total protein was subjected to immunoprecipitation
T-Cterm-pRb. Control lanes contain 100 Ag total protein from uninfected
Fig. 7. gHV68 v-cyclin complexes phosphorylate both cdk2 and cdc2
substrates. Cos-1 cells were transfected with pCMV-TAG2B vector control
(lanes 1 and 2), FLAG-v-cyclin (lanes 3 and 5), or FLAG-v-cyclin.E133V
(lane 4) and pCMV-cdk2 (lanes 2–5). 48 h post-transfection, cells were
harvested and immunoprecipitated with agarose-conjugated anti-FLAG
antibodies (Sigma). Immunoprecipitated complexes were resuspended in
kinase reaction buffer with p27Kip1 (2 Ag), 10 ACi gATP, and either 16 AM
roscovitine (+) or equivalent volume DMSO vehicle control (). The
reactions were allowed to proceed for 30 min at 37 -C. Reactions were
subjected to 12.5% SDS-PAGE followed by autoradiography. Gels were
dried and exposed to phosphor-screen for 12 h.
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observed lack of increase in pRb hyperphosphorylation upon
infection with v-cyclin.Stop virus, these data argue strongly
that the observed increase in pRb hyperphosphorylation is
due to expression of the gHV68 v-cyclin.
The CKI p27Kip1 is a negative regulator of Cdks and
cell cycle progression. Cyclin E:cdk2 is able to phos-
phorylate p27Kip1, targeting it for proteosomal degrada-
tion, thus facilitating cell cycle progression (Morisaki et
al., 1997; Sheaff et al., 1997). The KSHV v-cyclin:cdk6
complex has also been shown to possess the ability to
phosphorylate p27Kip1, targeting it for degradation and
thus bypassing p27Kip1 imposed growth arrest (Ellis et
al., 1999; Mann et al., 1999). To determine if the gHV68
v-cyclin is able to mediate phosphorylation of p27Kip1,
we immunoprecipitated FLAG-v-cyclin-containing com-
plexes from transfected Cos-1 cells for kinase assays,
using p27Kip1 as an exogenous substrate. Fig. 6A shows
that wild type gHV68 v-cyclin strongly phosphorylates
p27Kip1 in vitro and the phosphorylated substrate resolved
as a doublet, as is commonly seen (Montagnoli et al.,
1999). Additionally, the gHV68 v-cyclin E133V mutant
did not mediate phosphorylation of p27Kip1, providing
further evidence that the mutation introduced precludes
cdk binding and activation.
To further assess whether p27Kip1 is modulated during
the course of gHV68 infection, we infected serum-starved
murine NIH 3T3 fibroblasts with either wild type virus, v-
cyclin.Stop, or mock-infected cells, and followed the levels
of several cell cycle-associated gene products (Fig. 6B).
Notably, a significant increase in cdk2-associated kinase
activity was observed in wild type virus-infected cells that
was not apparent in either mock-infected or cells infected
with the v-cyclin.Stop mutant (Fig. 6B). Furthermore, the
increase in cdk2 kinase activity correlated precisely with the
rise in v-cyclin expression during the infection time course
(Fig. 6B). Concomitant with the increase in v-cyclin
expression and cdk2-associated kinase activity, there was a
sharp decrease in p27Kip1 levels, consistent with the v-cyclin
targeting p27Kip1 for degradation. Notably, there was also a
drop in p27Kip1 levels in v-cyclin.Stop-infected that was not
observed in mock-infected cells. However, this decrease in
p27Kip1 in v-cyclin.Stop-infected cells was delayed com-
pared to wild type virus-infected cells (Fig. 6B). Similarly,
in both wild type and v-cyclin.Stop-infected cells, there was
a decrease in cellular cyclin D expression that was not
observed in mock-infected cells (Fig. 6B). Taken together,
these data suggest that there is, in addition to v-cyclin
directed degradation of p27Kip1, a v-cyclin independent
shutoff of host gene expression during the course of virus
replication. We failed to detect a rise in cyclin A levels over
the time course analyzed (Fig. 6B). However, expression of
the early gene product of ORF 59 was readily detected with
the same kinetics in both wild type and v-cyclin.Stop-
infected cells (Fig. 6B). Levels of cdk2 and cdc2 did not
change over the course of the experiment, and kinaseactivity was not detected from cdc2 IP kinase assay (data
not shown).
cHV68 v-cyclin-mediated phosphorylation of cyclin A:cdk
substrates
The KSHV v-cyclin has been shown to bind cdk6 and
promote phosphorylation of a number of cell-cycle-related
proteins (Ellis et al., 1999; Godden-Kent et al., 1997; Laman
et al., 2001; Mann et al., 1999; Ojala et al., 2000; Swanton
et al., 1997). Recent work has also demonstrated that
expression of the KSHV v-cyclin in primary fibroblasts
leads to genomic instability and centrosome amplification,
underscoring the importance of proper checkpoint regula-
tion and the tumor suppressor p53 in preventing KSHV v-
cyclin-mediated tumorigenesis (Verschuren et al., 2002,
2004a, 2004b). Because we observed that the gHV68 v-
cyclin interacts with both cdk2 and cdc2, we investigated
whether gHV68 v-cyclin might play a role in later cell cycle
stages by phosphorylating components of the cell cycle
machinery associated with S and G2 phases of the cell
cycle. Fig. 7 shows that gHV68 v-cyclin-containing com-
plexes can phosphorylate p21Cip1, a known cyclin A:cdk
substrate (Bornstein et al., 2003; Jaumot et al., 1997), while
the gHV68 v-cyclin E133Vmutant exhibits only background
levels of p21Cip1 phosphorylation. Furthermore, the addition
of roscovitine, an inhibitor of cdc2 and cdk2, to the kinase
J.W. Upton et al. / Virology 341 (2005) 271–283 277reaction resulted in a significant reduction in the phosphory-
lation of p21Cip1.
To extend this analysis, we assessed two other substrates,
Bcl-2 and p53, as potential targets for the gHV68 v-
cyclin:cdk complexes. Bcl-2 is phosphorylated by cdc2
during G2/M, modulating its cell cycle regulatory properties
without affecting its anti-apoptotic function (Furukawa et
al., 2000). Also of note, the KSHV v-cyclin:cdk6 complex
has been shown to phosphorylate, and inactivate the anti-
apoptotic functions of Bcl-2 (Ojala et al., 2000). The tumor
suppressor p53 has also been shown to be a substrate for S/
G2 cyclin:cdk complexes (Addison et al., 1990; Bischoff
et al., 1990; Blaydes and Hupp, 1998; Luciani et al., 2000;
Wang and Prives, 1995). We found that gHV68 v-cyclin
complexes immunoprecipitated from Cos-1 cell were able to
phosphorylate both Bcl-2 and p53. As above, phosphor-
ylation was dependent on cdk binding since no activity was
observed with the v-cyclin E133V mutant. Furthermore,
phosphorylation was sensitive to the addition of roscovitine
to the kinase reaction (Fig. 7).Discussion
All g2-herpesviruses encode a v-cyclin that is conserved
in both sequence and position. We have previously shown
that the v-cyclin encoded by gHV68 promotes cell cycle
progression and tumorigenesis when expressed as a trans-
gene in mice and is a critical regulator of reactivation from
latency (van Dyk et al., 1999, 2000). Here, we extend the
analysis of the function of the gHV68 v-cyclin to show that
it binds multiple cdks and mediates phosphorylation of a
number of cell-cycle-related proteins in vitro.
Specific biochemical properties of the KSHV v-cyclin
have been a topic of intense research to determine how the
KSHV v-cyclin contributes to tumorigenesis (Verschuren et
al., 2004a, 2004b). The KSHV v-cyclin binds both G1 and
S-phase cdks but shows a marked preference for cdk6 and
allows for an expanded repertoire of phosphorylation
substrates for the kinase, including a number of critical cell
cycle genes. While it is known that gHV68 v-cyclin
interacts with cdk2, we sought to clarify which cdks the
gHV68 v-cyclin binds and activates in light of the
seemingly promiscuous activity of the KSHV v-cyclin.
We determined that the gHV68 v-cyclin binds cdk2 and
cdc2, but not cdk4 or cdk6 (Figs. 1, 2). This is in agreement
with previous reports that the v-cyclin interacts with cdk2,
and not the G1-associated cdk4 or cdk6 (Card et al., 2000).
However, there has previously been no description of a
herpesvirus v-cyclin binding cdc2. This makes the inter-
action between gHV68 v-cyclin and cdc2 a novel finding
among herpesvirus v-cyclins, although the implications of
cdc2 binding remain unclear. Since substrate specificity for
cyclin:cdk complexes is likely due to determinants imparted
by the cyclin (Goda et al., 2001; Horton and Templeton,
1997; Sarcevic et al., 1997; Schulman et al., 1998; Zarkowskaand Mittnacht, 1997), it will be interesting to determine
whether gHV68 v-cyclin promotes an expanded substrate
range for either or both cdk2 and cdc2 or whether binding of
the v-cyclin to each cdk allows for kinase activity only
toward traditional substrates associated with each.
Autographica californica nucleopolyhedrovirus encodes
a structural protein, ODV-EC27, that is a multi-functional
cyclin, binding to and activating cdc2 and cdk6 (Belyavskyi
et al., 1998). Although both complexes can phosphorylate
histone H1 and pRb, specific functions of each complex are
different; the cdc2:ODV-EC27 complex exhibits cyclin B-
like activity, while cdk6:ODV-EC27 is able to bind
proliferating cell nuclear antigen (PCNA), presumably to
aid establishment of an S-phase like cellular environment
(Belyavskyi et al., 1998). Whether gHV68 v-cyclin imparts
differential substrate preference upon its different binding
partners like ODV-EC27 or expands the substrate range of
each binding partner like the KSHV v-cyclin will be an
important point to investigate.
The herpes simplex virus-1 polymerase processivity
factor, UL-42, has been shown to directly interact with,
and activate, cdc2 to recruit topoisomerase IIa for the
expression of a subset of late genes (Advani et al., 2000,
2001, 2003). While it is tempting to speculate that the
gHV68 v-cyclin:cdc2 interaction may mediate similar
functions, it should be noted that gHV68 also encodes a
protein kinase, ORF36, which shares homology to kinases
ascribed cdc2-like functions in other herpesviruses (Kawa-
guchi and Kato, 2003; Kawaguchi et al., 2003). However,
ORF36 of gHV68 has not been characterized biochemically
or genetically, and, as such, it remains to be determined
whether it exhibits cdc2-like functions and/or whether there
is a role of the gHV68 v-cyclin:cdc2 complex in the
activation of late genes.
As discussed above, the structure of gHV68 v-cyclin in
complex with cdk2 has been determined (Card et al., 2000)
and, in addition to a number of novel interactions between
v-cyclin and cdk2, the gHV68 viral cyclin possesses a
number of conserved sequence and structural features
indicating that the v-cyclin binds to and activates cdk2 in
a manner similar to cellular cyclins. Based on these
findings, we hypothesized that mutation of residues
absolutely conserved among cyclins, both viral and cellular,
would abolish interaction between the v-cyclin and cdks. A
similar approach was taken in the biochemical character-
ization of the HVS v-cyclin, although that study focused on
multiple combinatorial mutations (Jung et al., 1994). We
chose two residues within the cyclin box of gHV68 that are
conserved in all known cyclins for substitutional mutation.
Side chains of the lysine residue at amino acid 104 and the
glutamate at amino acid 133 of the gHV68 v-cyclin both
participate in critical bonds between the gHV68 v-cyclin
and cdk2 (Card et al., 2000). We substituted a glutamate for
the lysine at position 104 (K104E) and, in independent
mutant, substituted a valine for the glutamate at position 133
(E133V). When assayed for interaction with cdk2 in
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cells, we observed that both the K104E and E133V
mutations severely impaired the ability of gHV68 v-cyclin
to bind cdk2. We chose to use the E133V mutant in further
experiments, and it was found to abolish kinase activity of
v-cyclin immunoprecipitates in vitro. Additionally, these
mutations abolish binding of cdc2 to the gHV68 v-cyclin,
further supporting the hypothesis that the gHV68 v-cyclin
engages cdks in a manner similar to cellular cyclins.
Mutation of the conserved lysine residue has been pre-
viously characterized for cyclin D1 and was found to cause
a defect in the ability of cyclin D1 to transform cells (Hinds
et al., 1994). Similarly, mutation of OrfA (rv-cyclin) of
walleye dermal sarcoma virus at the conserved lysine and
glutamate residues within the defined cyclin box abrogates
its ability to localize to the nucleus, a property potentially
mediated by additional components of the cyclin:cdk
complex (Rovnak et al., 2001). However, recent work
showed that mutation of the corresponding conserved lysine
of the KSHV v-cyclin does not appreciably affect binding to
cdk6 (Kaldis, 2005), although binding to other cdks was not
assessed. This characteristic appears specific to the KSHV
v-cyclin as these mutations in other cellular and viral cyclins
result in significant loss of function. How the previously
described novel features of the v-cyclin:cdk2 interaction
affect function of the complex remains to be determined,
although functions such as CKI resistance have been
proposed (Card et al., 2000).
KSHVand gHV68 v-cyclins have been shown, with their
cognate cdk, to phosphorylate pRb, and it is believed that
this phosphorylation results in cell cycle progression
necessary for the viral life cycle. Another g-herpesvirus,
Epstein–Barr virus (EBV), although it does not encode a v-
cyclin, uses a similar mechanism to push cells into cycle by
inducing the expression of cyclin D2 (Arvanitakis et al.,
1995). An obvious consequence of such direct cell cycle
manipulation is tumorigenesis, and both the KSHV v-cyclin
and gHV68 v-cyclin have been shown to be oncogenic
when expressed as lymphocyte-specific transgenes in mice
(van Dyk et al., 1999; Verschuren et al., 2002, 2004a,
2004b), although the specific role of pRb phosphorylation
and inactivation in tumorigenesis by v-cyclins has not been
directly assessed. In the context of lytic virus infection, the
gHV68 v-cyclin is necessary for the hyperphosphorylation
of pRb characteristic of cell cycle progression since a
recombinant virus lacking v-cyclin fails to induce a similar
level of pRb phosphorylation. However, it should be noted
that the gHV68 v-cyclin is not required for virus replication,
in vitro or in vivo (Hoge et al., 2000; van Dyk et al., 2000),
and thus pRb phosphorylation is likely not required for the
completion of the lytic program. The gHV68 v-cyclin is
required for efficient reactivation from latency. While little
is known about the role of pRb in viral latency, it is tempting
to speculate that pRb phosphorylation may be a critical
step in the process of reactivation from a quiescent cell
population.Cyclin E:cdk2 and the KSHV v-cyclin:cdk6 complexes
have both been shown to phosphorylate p27Kip1, targeting it
for proteosomal degradation (Ellis et al., 1999; Mann et al.,
1999; Montagnoli et al., 1999; Morisaki et al., 1997;
Shirane et al., 1999; Sutterluty et al., 1999; Vlach et al.,
1997). Phosphorylation and eventual degradation of CKIs
by v-cyclins represents another mechanism by which v-
cyclins alter the normal host cell cycle. More recently, the
KSHV v-cyclin was shown to bind to p27Kip1 in primary
effusion lymphoma (PEL) cells, which have been shown to
express high levels of the CKI (Jarviluoma et al., 2004),
underscoring the potential importance of v-cyclins in
modulating p27Kip1 activity. p27Kip1 is an in vitro substrate
for the gHV68 v-cyclin:cdk complex, and expression of v-
cyclin during infection correlates directly with accelerated
degradation of p27Kip1. It is interesting to note that p27Kip1
levels also decline in cells infected with a v-cyclin null
virus, although with delayed kinetics. Levels of D-type
cyclins also gradually decrease in both wild type and
mutant-infected cells with strikingly similar kinetics. It is
likely that other virally encoded mechanisms enhance
ubiquitination and proteosomal degradation of cellular
targets as both p27Kip1 and D-type cyclins are regulated
by these processes (Diehl et al., 1997; Shirane et al., 1999;
Sutterluty et al., 1999). However, the presence of v-cyclin
during infection enhances the rate of p27Kip1 degradation,
while D-type cyclin levels are unaffected. Taken together,
these findings indicate that p27Kip1 is a substrate for v-
cyclin:cdk complexes, which target it for destruction.
Establishment of an S-phase environment is hypothe-
sized to be necessary for viral replication. While expression
of the gHV68 v-cyclin induces markers of the G1 to S
transition (i.e. pRB hyperphosphorylation and p27Kip1
degradation), it is not known whether v-cyclin expression
can drive entry into S-phase during infection. Cyclin A is
the canonical marker for, and is necessary for progression
through, S-phase. Surprisingly, cyclin Awas not appreciably
upregulated in infected samples, similar to mock infection
and in stark contrast to uninfected actively dividing cells.
While this indicates that contact inhibition and serum
starvation were sufficient to arrest cells in G0/early G1, it
also suggests that an S-phase conducive to cellular
replication is not initiated. It appears that other viral factors
may be responsible for this phenomenon since wild type and
v-cyclin.Stop-infected cells are similar in this respect,
despite the ability of v-cyclin to affect cellular processes
that would normally induce S-phase and cyclin A expres-
sion. One possibility is that gHV68 v-cyclin is necessary to
enhance specific cdk activities, while other viral factors
subvert normal cell cycle progression. Cyclin A:cdk
complexes have been shown to associate with and phos-
phorylate p21Cip1 (Bornstein et al., 2003; Jaumot et al.,
1997). Since cyclin A is not induced during infection, it is
possible that the gHV68 v-cyclin performs functions usually
ascribed to cyclin A. We have shown here that v-cyclin:cdk
complexes are able to phosphorylate p21Cip1 in vitro in a
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of p21Cip1 phosphorylation by cdks, whether targeting it for
degradation or enhancing G2 cdk activity, remain contro-
versial (Cayrol and Ducommun, 1998; Dash and El-Deiry,
2005), and it will be interesting to determine whether v-
cyclin-mediated phosphorylation of p21Cip1 has specific
effects.
Co-expression of KSHV v-cyclin and cdk6 in U2-OS
osteosarcoma cells induces apoptosis mediated by phos-
phorylation and inactivation of Bcl-2, which can be reversed
by expression of the KSHV v-Bcl-2 (Ojala et al., 1999).
Since gHV68 also encodes a v-Bcl-2 and because Bcl-2 is
phosphorylated during G2/M phase by cdc2 (Furukawa et
al., 2000), we assessed Bcl2 phosphorylated and demon-
strated that the gHV68 v-cyclin:cdk complex can phosphor-
ylate Bcl-2 in vitro (Fig. 7) and determined that this
phosphorylation is sensitive to inhibition by the cdc2/cdk2
inhibitor roscovitine. Whether the gHV68 v-cyclin phos-
phorylates Bcl-2 while in complex with cdk2 or with cdc2
and the in vivo consequences remain to be determined.
Another cellular factor intimately involved in cell cycle
regulation and survival is the tumor suppressor p53. It is
subject to a myriad of post-translational modifications with
varying effects on its function (Xu, 2003). p53 possesses a
cdk phosphorylation site and is phosphorylated by both
cdc2 and cdk2 in vitro (Addison et al., 1990; Bischoff
et al., 1990; Blaydes and Hupp, 1998; Luciani et al., 2000;
Wang and Prives, 1995). However, the in vivo effects
of phosphorylation by cdks are poorly understood. We
determined that p53 can be phosphorylated in vitro by v-
cyclin-containing complexes. Whether this activity is bio-
logically relevant remains to be determined. There has been
no report of the KSHV v-cyclin interacting with p53,
although loss of p53 function uncovers the oncogenic
potential of the KSHV v-cyclin in transgenic mice
(Verschuren et al., 2004a, 2004b). Notably, the oncogenic
potential of the gHV68 v-cyclin was readily observed in
normal mice (e.g., did not require crossing the v-cyclin
transgenic mice onto a p53 null background), perhaps
suggesting that a distinguishing feature of the gHV68 and
KSHV v-cyclins is the ability of the gHV68 v-cyclin to
target and inactivate p53. However, in the context of a latent
KSHV infection, KSHV latent nuclear antigen (LANA)
expression leads to p53 inactivation (Friborg et al., 1999;
Wong et al., 2004), further indicating that suppression of the
p53 pathway is important during virus infection. Finally,
cyclin A:cdk2 complexes have been shown to regulate
protein–protein interactions of MDM2 by phosphorylation
(Zhang and Prives, 2001), which functions to downregulate
p53 protein levels and activity (Momand et al., 2000).
Further studies will be required to determine whether p53
function is regulated during latent gHV68 infection and
whether modulation of p53 activity through phosphorylation
by v-cyclin:cdk complexes occurs.
In summary, we have shown that the gHV68 v-cyclin
binds cdc2 and cdk2, activates cdks in a manner similar tocellular cyclins, and directs them in the phosphorylation of a
number of components of the cell cycle machinery. In the
context of ectopic expression in transgenic mice, the gHV68
v-cyclin is an oncogene, while in the context of virus
infection, it is a critical regulator of reactivation from
latency. It is likely that these functions are intertwined in the
signaling pathways affected by the gHV68 v-cyclin, and
careful dissection of these pathways may lead to a better
understanding of the link between the cell cycle, g-
herpesvirus tumorigenesis, and g-herpesvirus reactivation.Materials and methods
Cell culture
NIH3T12 (ATCC CCL-164), NIH3T3 (ATCC CCL-
163), and Cos-1 cells (ATCC CLR-1650) were grown and
maintained at 37 -C and 5% CO2 in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% fetal calf
serum (FCS), 100 U penicillin/ml, 100 mg streptomycin/ml,
and 2 mM l-glutamine.
Reagents
To generate an expression vector encoding a FLAG
epitope-tagged v-cyclin (FLAG-v-cyclin), the gHV68 v-
cyclin open reading frame was amplified by PCR from
gHV68 genomic DNA with primers incorporating BamH1
and Xho1 restriction sites using Vent polymerase (New
England Biolabs). PCR products were sub-cloned into pCR-
Blunt (Invitrogen) and the sequence confirmed. The v-
cyclin was then shuttled into the BamH1/Xho1 sites of
pCMV-TAG2B (Stratagene), providing an in-frame amino-
terminal FLAG-tag. K104E and E133V mutations were
generated by 2-part overlapping PCR, introducing the
indicated mutation and silent mutations generating unique
restriction sites at or near the site of the coding mutation,
and cloned as described above. Primers used to generate
the K104E mutant were juK104ES (5V-CTCCATATC
GCCGGCGAGGTCAGGGCCTACATG-3V) and juK104-
EC (5V-CATGTAGG CCCTGACCTCGCCGGCGATATG-
GAG-3V). Primers used to generate E133V mutant were
juE133VS (5V-GCTGACAAACTATTGACACTAGTAG-
TCAAAAGTCTG GATACCCTCTCGTGGG-3V) and
juE133VC (5V-CCCACGAGAGGGTATCCA GACTTTT-
GACTACTAGTGTCAATAGTTTGTCAGC-3V). Bold let-
ters represent silent mutations to generate the unique
restriction sites depicted in italics (NaeI for K104E and
SpeI for E133V), and underlined letters produce the coding
mutations indicated by each name designation. Cyclin E and
cyclin D3 expression constructs were generated by RT-PCR
amplification from murine fibroblast RNA, using gene
specific primers incorporating BamH1 and Xho1 restriction
sites at the 5Vand 3Vends of the cDNA, respectively. Cyclin
D1 cDNA (38a) was amplified in the same fashion. PCR
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sequenced, and cloned in frame into pCMV-TAG2B as
described above.
pCMV-cdk6 and pCMV-cdk2 were kind gifts from Matt
Meyerson (Dana Farber Cancer Institute). Cdk4 was PCR
amplified from cDNA prepared from mouse embryonic
fibroblasts with gene specific primers incorporating a Kozak
consensus translation initiation sequence (Kozak, 1987).
The PCR product was blunt-cloned into pCMV-Script
(Strategene) and confirmed by sequencing. pCMV-cdc2
was constructed by shuttling the BamH1/EcoR1 fragment of
pSAF10-cdc2 (a gift from Helen Piwnica-Worms, Wash-
ington University School of Medicine) into the same unique
sites of pCMV-Script (Strategene). Antibodies used in this
study were: rabbit polyclonal anti-cdc2 (C-19, Santa Cruz
Biotechnology), goat polyclonal anti-cdk2 (M2, Santa Cruz
Biotechnology), goat polyclonal anti-cdk4 (C-22, Santa
Cruz Biotechnology), goat polyclonal anti-cdk6 (C-21,
Santa Cruz Biotechnology), rabbit polyclonal anti-pRb (C-
15, Santa Cruz Biotechnology), mouse monoclonal anti-
p27Kip1 (F-8, Santa Cruz Biotechnology), rabbit polyclonal
anti-cyclin D3 (H292, Santa Cruz Biotechnology), rabbit
polyclonal anti-cyclin A (C-19, Santa Cruz Biotechnology),
mouse monoclonal anti-FLAG-HRP (M2, Sigma), mouse
monoclonal anti-h-actin-FITC conjugate (Sigma), and
rabbit anti-gHV68 v-cyclin antisera (van Dyk et al.,
1999). Affinity-purified chicken polyclonal anti-ORF59
antibodies (Gallus Immunotech) were generated against
the peptides GKKTRGGNKASDSGT and KRPPP-
KKDREPTTKRPKL, corresponding to amino acids 210–
224 and 372–388, respectively, of the predicted ORF59
protein of gHV68 (Genbank:AAF19323). Donkey anti-
mouse, anti-goat, and anti-rabbit antibodies conjugated with
horseradish peroxidase (Jackson Immunochemicals) and
donkey anti-chicken–HRP (Gallus Immunotech) were used
as secondary antibodies in Western analysis. Normal rabbit
IgG–, rabbit anti-cdk2 (M2)–, anti-cdk4 (C-22)–, anti-
cdk6 (C-21)–, and mouse anti-cdc2 (17)–agarose conju-
gates were purchased from Santa Cruz Biotechnology. Re-
combinant proteins p27Kip1, GST-Cterm-pRb, GST-p21Cip1,
GST-Bcl-2, GST-p53, GST (Santa Cruz), and histone H1
(Upstate) were used as exogenous substrates for in vitro
kinase assays.
Co-immunoprecipitation and immunoblotting
106 Cos-1 cells were plated in 10 cm dishes and allowed
to adhere overnight. Cells were then transfected with 10 Ag
FLAG-v-cyclin and 10 Ag of cdk expression vectors using
the LT-1 transfection reagent (Mirus) according to the
manufacturer’s instructions. 48 h post-transfection, cells
were washed with phosphate-buffered saline and lysed in
500 Al ELB buffer (50 mM HEPES pH 7.2, 250 mM NaCl, 2
mM EDTA, 0.1% NP-40 substitute, 1 mM NaF, 1 mM
Na3VO4, and 0.01% protease inhibitor cocktail (Sigma)) for
20 min at 4 -C. Cells were then scraped into Eppendorf tubesand cleared of cellular debris by centrifugation. Lysates were
precleared with normal mouse IgG-Agarose (Santa Cruz) for
1 h at 4 -C with agitation. Lysates were once again cleared
by centrifugation and incubated overnight with 25 Al anti-
FLAG (M2) agarose beads (Sigma). Beads were washed 4
times in cold ELB, boiled for 10 min in SDS loading buffer,
and subjected to SDS-PAGE. Proteins were transferred to
Hybond-ECL nitrocellulose membranes (Amersham Bio-
sciences) and immunoblotted with the indicated antibody.
Some membranes were stripped with 0.2 M NaOH for 5 min,
washed with de-ionized water, re-blocked, and re-immuno-
blotted, as indicated. Membranes were visualized by
enhanced chemiluminescence using the ECL Western Blot-
ting Detection System (Amersham Biosciences).
Kinase assays
Cos-1 cells were transfected with 10 Ag FLAG-v-cyclin
and 10 Ag pCMV-cdk2 and harvested as described above.
Lysates from 2 independent transfections were pooled,
aliquoted into 3 samples, and then immunoprecipitated with
anti-FLAG beads as described above. Beads were washed 4
times with cold ELB, 2 times with cold 50 mM Tris pH 7.4,
10 mM MgCl2, and each sample divided into two parts.
Each pellet was re-suspended 25 Al in kinase reaction buffer
(50 mM Tris 7.4, 10 mM MgCl2, 1 mM DTT, 250 AM ATP)
with 2 Ag of exogenous substrate and 10 ACi g32P-ATP. In
experiments assessing chemical inhibition of kinase com-
plexes, 4 Al of a 100 AM stock of roscovitine (Calbiochem)
or vehicle control (DMSO, Sigma) was added to the reaction
where indicated (for a final concentration of 16 AM) prior to
incubation. Reactions were allowed to proceed for 30 min at
37 -C, terminated with the addition of an equal volume of
2 SDS loading buffer, boiled for 10 min, and subjected to
SDS-PAGE. Gels were dried and visualized by autoradiog-
raphy. For kinase assays following cdk depletion, 5  106
Cos-1 cells were transfected with 50 Ag FLAG-v-cyclin. 48
h post-transfection, cells were harvested, and equivalent
lysates were subjected to three rounds of immunodepletion
of indicated cdks using 30 Al of agarose-conjugated cdk-
specific antibodies. Following the final immunodepletion,
lysates were immunoprecipitated with 25 Al anti-FLAG
(M2) agarose beads and processed as described above.
Infections and viruses
NIH 3T12 cells were seeded in 10 cm dishes and serum-
starved for 72 h in low serum media (DMEM supplemented
with 0.5% FCS, 100 U ml/penicillin, 100 mg/ml strepto-
mycin, and 2 mM l-glutamine). Cells were then infected at
MOI = 5.0 with wild type gHV68 clone WUMS
(ATCCVR1465), v-cyclin.Stop (van Dyk et al., 2000), or
mock-infected in a volume of 2 ml (with serum concen-
tration not exceeding 0.5%) for 1 h at 37 -C with occasional
rocking. Following infection, 8 ml of serum low media was
added for the remainder of the infection. Cells were then
J.W. Upton et al. / Virology 341 (2005) 271–283 281harvested and lysed in ELB at the indicated times. Protein
concentrations were calculated using the DC Protein Assay
(Bio-Rad). 50 Ag of total protein per lane was subjected to
SDS-PAGE and Western blotting. NIH3T3 cells were
seeded and allowed to grow to confluence. Media was then
replaced with low serum media for 72 h to allow for serum
starvation. Cells were infected as described above at MOI =
10.0 in low serum media for 1 h, washed twice in PBS, and
replenished with low serum media until indicated harvest
times. Cells were harvested, and protein determined, as
described above. 100 Ag of total protein was subjected to
SDS-PAGE and Western blot analysis. Infected cell kinase
assays were performed on lysates containing 300 Ag total
protein in a total volume of 500 Al ELB as described above
using 25 Al of rabbit anti-cdk2 (M2)–agarose slurry (Santa
Cruz) for immunoprecipitation and GST-Cterm-pRb as
exogenous substrate.Acknowledgments
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